Status: Currently Official on 14-Feb-2025
Official Date: Official as of 27-Mar-2024
Document Type: USP Monographs
DocId: GUID-98FFD64B-5EBE-4474-A556-E1996987BA0E_2_en-US
DOI: https://doi.org/10.31003/USPNF_M39430_02_01
DOI Ref: 9ueaz

Hydroxyurea Capsules

To view the Notice from the Expert Committee that posted in conjunction with this accelerated revision, please click https://www.uspnf.com/rb-hydroxyurea-caps-20240426 .

DEFINITION
Hydroxyurea Capsules contain NLT 90.0% and NMT 110.0% of the labeled amount of hydroxyurea ($CH_4N_2O_2$).

IDENTIFICATION

• **A.**

Standard: Transfer 30 mg of USP Hydroxyurea RS to a suitable centrifuge tube, and add 10 mL of anhydrous methanol. Centrifuge for 3 min. Transfer 1.0 mL of the clear supernatant to a mortar containing 500 mg of potassium bromide, triturate to a homogeneous blend, dry in a vacuum desiccator at 60° for 3 h, and prepare a suitable disk.

Sample: Transfer a portion of Capsule contents, equivalent to 30 mg of hydroxyurea, to a suitable centrifuge tube, and add 10 mL of anhydrous methanol. Centrifuge for 3 min. Transfer 1.0 mL of the clear supernatant to a mortar containing 500 mg of potassium bromide, triturate to a homogeneous blend, dry in a vacuum desiccator at 60° for 3 h, and prepare a suitable disk.

Acceptance criteria: The IR absorption spectrum of the *Sample* exhibits maxima only at the same wavenumbers as that of the *Standard*.

ASSAY

• **Procedure**

Solution A: Dissolve 1.7 g of tetrabutylammonium hydrogen sulfate and 1.74 g of dibasic potassium phosphate in 1000 mL of water. Adjust with 1 N sodium hydroxide or phosphoric acid to a pH of 5.0.

Mobile phase: Methanol and *Solution A* (15:85)

System suitability solution: 0.4 mg/mL each of USP Hydroxyurea RS and hydroxylamine hydrochloride in *Mobile phase*

Standard solution: 0.4 mg/mL of USP Hydroxyurea RS in *Mobile phase*

Sample solution: Nominally 0.4 mg/mL of hydroxyurea in *Mobile phase* prepared as follows. Remove, as completely as possible, the contents of NLT 20 Capsules and grind to a fine powder. Transfer a portion of the powder, equivalent to 200 mg of hydroxyurea, to a 500-mL volumetric flask. Add 300 mL of *Mobile phase*, sonicate for 10 min, stir with the aid of a magnetic stirrer for 30 min, sonicate for an additional 10 min, and dilute with *Mobile phase* to volume. Filter a portion of the resulting solution, discarding the first 2 mL of the filtrate.

Chromatographic system

(See *Chromatography ⟨621⟩, System Suitability*.)

Mode: LC

Detector: UV 214 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Flow rate: 0.5 mL/min

Injection volume: 10 µL

System suitability

Samples: *System suitability solution* and *Standard solution*

Suitability requirements

Resolution: NLT 1.5 between hydroxylamine and hydroxyurea, *System suitability solution*

Column efficiency: NLT 5000 for hydroxyurea, *System suitability solution*

Tailing factor: NMT 1.5 for hydroxyurea, *System suitability solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of hydroxyurea ($CH_4N_2O_2$) in the portion of Capsules taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response of hydroxyurea from the *Sample solution*

r_S = peak response of hydroxyurea from the *Standard solution*

C_S = concentration of USP Hydroxyurea RS in the *Standard solution* (mg/mL)

C_U = nominal concentration of hydroxyurea in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

Change to read:

• **Dissolution** ⟨711⟩

▲**Test 1**▲ (RB 27-Mar-2024)

Medium: Water; 500 mL

Apparatus 2: 50 rpm

Time: 30 min

Analysis: Calculate the percentage of the labeled amount of hydroxyurea ($CH_4N_2O_2$) dissolved by using the procedure set forth in the *Assay*, making any necessary modifications.

Tolerances: NLT 80% (Q) of the labeled amount of hydroxyurea ($CH_4N_2O_2$) is dissolved.

▲**Test 2:** If the product complies with this test, the labeling indicates that it meets USP *Dissolution Test 2*.

Medium: 0.1 N hydrochloric acid; 500 mL

Apparatus 2: 50 rpm

Time: 30 min

Buffer: Dissolve 1.7 g of tetrabutylammonium hydrogen sulfate and 1.74 g of dibasic potassium phosphate in 1000 mL of water. Adjust with phosphoric acid to a pH of 5.0.

Mobile phase: Methanol and *Buffer* (15:85)

Standard solution: (*L*/500) mg/mL of USP Hydroxyurea RS in *Medium*, where *L* is the label claim in mg/Capsule

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45-µm pore size, discarding an appropriate volume of filtrate so that a consistent result can be obtained.

Chromatographic system

(See *Chromatography* ⟨621⟩, *System Suitability*.)

Mode: LC

Detector: UV 214 nm

Column: 4.6-mm × 25-cm; 5-µm packing L1

Column temperature: 30°

Flow rate: 0.5 mL/min

Injection volume: 10 µL

Run time: NLT 4.5 times the retention time of hydroxyurea

System suitability

Sample: *Standard solution*

Suitability requirements

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of hydroxyurea ($CH_4N_2O_2$) dissolved:

$$\text{Result} = (r_U/r_S) \times C_S \times V \times (1/L) \times 100$$

r_U = peak response of hydroxyurea from the *Sample solution*

r_S = peak response of hydroxyurea from the *Standard solution*

C_S = concentration of USP Hydroxyurea RS in the *Standard solution* (mg/mL)

V = volume of *Medium*, 500 mL

L = label claim (mg/Capsule)

Tolerances: NLT 80% (*Q*) of the labeled amount of hydroxyurea ($CH_4N_2O_2$) is dissolved.▲ (RB 27-Mar-2024)

• **Uniformity of Dosage Units** ⟨905⟩**:** Meet the requirements

ADDITIONAL REQUIREMENTS

• **Packaging and Storage:** Preserve in tight containers, in a dry atmosphere.

Add the following:

▲• **Labeling:** The labeling states the *Dissolution* test used only if *Test 1* is not used.▲ (RB 27-Mar-2024)

• **USP Reference Standards** ⟨11⟩

USP Hydroxyurea RS

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

Topic/Question	Contact	Expert Committee
HYDROXYUREA CAPSULES	Documentary Standards Support	SM32020 Small Molecules 3

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:
Pharmacopeial Forum: Volume No. PF 29(6)

Current DocID: GUID-98FFD64B-5EBE-4474-A556-E1996987BA0E_2_en-US

DOI: https://doi.org/10.31003/USPNF_M39430_02_01

DOI ref: 9ueaz